NKGen Biotech, Inc. Common Stock
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease… Read more
NKGen Biotech, Inc. Common Stock (NKGN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.056x
Based on the latest financial reports, NKGen Biotech, Inc. Common Stock (NKGN) has a cash flow conversion efficiency ratio of 0.056x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.80 Million) by net assets ($-50.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NKGen Biotech, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2023)
This chart illustrates how NKGen Biotech, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
NKGen Biotech, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NKGen Biotech, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CT AUTOMOTIVE GROUP -005
F:X7X
|
N/A |
|
Boldt S.A
BA:BOLT
|
0.092x |
|
EPB Group Berhad
KLSE:0317
|
0.094x |
|
Repower Asia Indonesia PT
JK:REAL
|
-0.040x |
|
GUANGDONG KANG.CO.LTD YC1
F:E9Q
|
N/A |
|
Odonate Therapeutics
PINK:ODTC
|
0.054x |
|
Keystone Reit Ltd
TA:KSTN
|
-0.007x |
|
Nico Resources Ltd
AU:NC1
|
0.020x |
Annual Cash Flow Conversion Efficiency for NKGen Biotech, Inc. Common Stock (2021–2023)
The table below shows the annual cash flow conversion efficiency of NKGen Biotech, Inc. Common Stock from 2021 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-58.69 Million | $-21.95 Million | 0.374x | +102.59% |
| 2022-12-31 | $1.56 Million | $-22.56 Million | -14.432x | -2909.30% |
| 2021-12-31 | $-38.05 Million | $-19.55 Million | 0.514x | -- |